Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors
In a comparison of the PNET and NSCLC groups, having a ProGRP value higher than 84.6 pg/mL revealed PNET with 60.9% sensitivity and 89.3% specificity (P = 0.001).Conclusion: The ProGRP value is the only indicator that distinguishes the PNET group from the other 3 groups.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: It is not always easy to diagnose pulmonary neuroendocrine tumors (PNETs).
📊
Key Findings & Data:The aim of the present study is to makea differential diagnosis by studying the same markers in patients with non-small-cell lung carcinoma (NSCLC), patients with benignlung disease (chronic obstructive pulmonary disease and pneumonia), and healthy volunteers to determine the roles of these markersin pulmonary neuroendocrine tumor diagnosis and to identify their power.Materials and methods: A total of 100 participants including 23 PNET patients and 28 NSCLC patients who were pathologically diagnosed but not yet treated, 25 participants with benign disease, and 24 healthy volunteers were included in this cross-sectional study.Results: No significant difference was found between the chromogranin A (CgA) and squamous cell carcinoma antigen 1 (SCCA1)values among the groups (PNET, NSCLC, benign, healthy volunteers), but the difference in progesterone-releasing peptide (ProGRP),neuron-specific enolase (NSE), and adjusted NSE was statistically significant (P values were respectively ProGRP, P = 0.006; NSE, P =0.015; NSE adjusted, P = 0.09).
💡
Conclusion & Impact:In a comparison of the PNET and NSCLC groups, having a ProGRP value higher than 84.6 pg/mL revealed PNET with 60.9% sensitivity and 89.3% specificity (P = 0.001).Conclusion: The ProGRP value is the only indicator that distinguishes the PNET group from the other 3 groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Background/aim: It is not always easy to diagnose pulmonary neuroendocrine tumors (PNETs). The aim of the present study is to makea differential diagnosis by studying the same markers in patients with non-small-cell lung carcinoma (NSCLC), patients with benignlung disease (chronic obstructive pulmonary disease and pneumonia), and healthy volunteers to determine the roles of these markersin pulmonary neuroendocrine tumor diagnosis and to identify their power.Materials and methods: A total of 100 participants including 23 PNET patients and 28 NSCLC patients who were pathologically diagnosed but not yet treated, 25 participants with benign disease, and 24 healthy volunteers were included in this cross-sectional study.Results: No significant difference was found between the chromogranin A (CgA) and squamous cell carcinoma antigen 1 (SCCA1)values among the groups (PNET, NSCLC, benign, healthy volunteers), but the difference in progesterone-releasing peptide (ProGRP),neuron-specific enolase (NSE), and adjusted NSE was statistically significant (P values were respectively ProGRP, P = 0.006; NSE, P =0.015; NSE adjusted, P = 0.09). In a comparison of the PNET and NSCLC groups, having a ProGRP value higher than 84.6 pg/mL revealed PNET with 60.9% sensitivity and 89.3% specificity (P = 0.001).Conclusion: The ProGRP value is the only indicator that distinguishes the PNET group from the other 3 groups.
🔖
Cite This Article
ÖNAL, Ö., YAZICI, C., KONTAŞ, O., KELEŞTEMUR, F., TUTAR, N., YETKİN, N. A. (2022). Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 3, 774–781. https://ajindex.com/articles/609988
Govindan R, Page N, Morgensztern D, Read W, Tierney R et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006; 24 (28): 4539-4544
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network 2013; 11 (1): 78-98
Öberg K, Hellman P, Kwekkeboom D, Jelic S; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010; 21 (Suppl. 5): v220-v222
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology 2015; 26 (8): 1604-1620
Detterbeck FC. Management of carcinoid tumors. Annals of Thoracic Surgery 2010; 89 (3): 998-1005
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113 (1): 5-21
Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Annals of Thoracic and Cardiovascular Surgery 1999; 5 (4): 211-219
Travis W. Advances in neuroendocrine lung tumors. Annals of Oncology 2010; 21 (Suppl. 7): vii65-vii71
Lamy PJ, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000; 29 (3): 197-203
Molina R, Auge JM, Alicarte J, Filella X, Viñolas N et al. Progastrin-releasing peptide in patients with benign and malignant diseases. Tumor Biology 2004; 25 (1-2): 56-61
Nisman B, Biran H, Ramu N, Heching N, Barak V et al. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Research 2009; 29 (11): 4827-4832
Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clinical Cancer Research 1997; 3 (1): 123-127
Stieber P, Dienemann H, Schalhorn A, Schmitt U, Reinmiedl J et al. Pro-gastrin-releasing peptide (ProGRP): a useful marker in small cell lung carcinomas. Anticancer Research